Goldman Sachs Group Inc Seres Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 74,629 shares of MCRB stock, worth $573,150. This represents 0.0% of its overall portfolio holdings.

Number of Shares
74,629
Previous 74,629 -0.0%
Holding current value
$573,150
Previous $52,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
BUY
$0.64 - $0.91 $13,874 - $19,727
21,679 Added 40.94%
74,629 $52,000
Q4 2024

Feb 11, 2025
BUY
$0.55 - $0.98 $21,055 - $37,516
38,282 Added 260.99%
52,950 $43,000
Q3 2024

Nov 14, 2024
SELL
$0.7 - $1.48 $456,598 - $965,378
-652,283 Reduced 97.8%
14,668 $13,000
Q2 2024

Aug 13, 2024
SELL
$0.56 - $1.19 $222,424 - $472,651
-397,186 Reduced 37.32%
666,951 $480,000
Q1 2024

May 15, 2024
BUY
$0.75 - $1.56 $471,206 - $980,109
628,275 Added 144.15%
1,064,137 $819,000
Q4 2023

Feb 13, 2024
SELL
$0.93 - $2.15 $246,450 - $569,752
-265,001 Reduced 37.81%
435,862 $610,000
Q3 2023

May 14, 2024
BUY
$2.33 - $5.07 $617,452 - $1.34 Million
265,001 Added 60.8%
700,863 $1.67 Million
Q3 2023

Nov 14, 2023
BUY
$2.33 - $5.07 $102,680 - $223,429
44,069 Added 6.71%
700,863 $1.67 Million
Q2 2023

May 14, 2024
BUY
$4.67 - $6.55 $1.57 Million - $2.2 Million
336,046 Added 104.77%
656,794 $3.15 Million
Q2 2023

Aug 14, 2023
BUY
$4.67 - $6.55 $1.57 Million - $2.2 Million
336,046 Added 104.77%
656,794 $3.15 Million
Q1 2023

May 14, 2024
SELL
$4.95 - $6.09 $67,542 - $83,098
-13,645 Reduced 4.08%
320,748 $1.82 Million
Q1 2023

May 11, 2023
SELL
$4.95 - $6.09 $67,542 - $83,098
-13,645 Reduced 4.08%
320,748 $1.82 Million
Q4 2022

May 14, 2024
BUY
$5.09 - $9.05 $350,507 - $623,201
68,862 Added 25.93%
334,393 $1.87 Million
Q4 2022

Feb 13, 2023
BUY
$5.09 - $9.05 $350,507 - $623,201
68,862 Added 25.93%
334,393 $1.87 Million
Q3 2022

May 14, 2024
SELL
$3.5 - $7.2 $721,059 - $1.48 Million
-206,017 Reduced 43.69%
265,531 $1.71 Million
Q3 2022

Nov 10, 2022
SELL
$3.5 - $7.2 $721,059 - $1.48 Million
-206,017 Reduced 43.69%
265,531 $1.7 Million
Q2 2022

May 14, 2024
BUY
$2.7 - $7.62 $96,352 - $271,927
35,686 Added 8.19%
471,548 $1.62 Million
Q2 2022

Aug 15, 2022
SELL
$2.7 - $7.62 $423,902 - $1.2 Million
-157,001 Reduced 24.98%
471,548 $1.62 Million
Q1 2022

May 16, 2022
SELL
$6.3 - $8.84 $3.84 Million - $5.39 Million
-609,901 Reduced 49.25%
628,549 $4.48 Million
Q4 2021

Feb 14, 2022
BUY
$6.02 - $11.43 $4.01 Million - $7.62 Million
666,935 Added 116.7%
1,238,450 $10.3 Million
Q3 2021

Nov 10, 2021
BUY
$5.46 - $22.6 $3.12 Million - $12.9 Million
571,515 New
571,515 $3.98 Million

Others Institutions Holding MCRB

# of Institutions
65
Shares Held
39.5M
Call Options Held
103K
Put Options Held
53K
View Full List

About Seres Therapeutics, Inc.

MCRB Quotes by TradingView
  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $953M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email